# SAFETY OF 8-AMINOQUINOLINE ANTIMALARIAL MEDICINES

JUDITH RECHT, ELIZABETH ASHLEY AND NICHOLAS WHITE



A CALLED A DE LA DELLA DE LA DELLA DELLA DE LA DELLA DE LA DELLA DELLA





WHO Library Cataloguing-in-Publication Data:

Safety of 8-aminoquinoline antimalarial medicines.

1. Malaria, Vivax – drug therapy. 2. Malaria – Falciparum – drug therapy. 3. Aminoquinolines – administration and dosage. 4. Aminoquinolines – adverse effects. 5. Primaquine. 6. Antimalarials. I. Recht, Judith. II. Ashley, Elizabeth. III. White, Nicholas. IV. World Health Organization. V. Mahidol Oxford Research Unit.

ISBN 978 92 4 150697 7

(NLM classification: QV 256)

#### © World Health Organization 2014

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/ about/licensing/copyright\_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Editing: Elisabeth Heseltine Design: elfiga Cover photo: Shoklo Malaria Research Unit Cover illustration: Denis Meissner, WHO Graphics Printed in Malta

## Contents

Abbreviations Acknowlegements		
Executive summary		
1.	8-Aminoquinolines	19
1.1	Pamaquine, the predecessor of primaquine	20
1.1.1	Use for malaria prophylaxis	20
1.1.2	Use to prevent relapses of vivax malaria	21
1.1.3	Use as a gametocytocide	22
1.1.4	Activity against blood stages	23
1.1.5	Toxicity	25
1.2	Pentaquine	28
1.3	Primaquine	30
1.3.1	Pharmacology	30
1.3.2	Antimalarial action	32
1.4	Quinocide	33
1.5	Bulaquine (elubaquine)	35
1.6	Tafenoquine	36
2.	Efficacy of primaquine as an antimalarial drug	39
2.1	Malaria prophylaxis	40
2.2	Prevention of relapse of vivax malaria	41
2.2.1	14-day regimens	44
2.2.2	Shorter regimens	45
2.2.3	Total dose versus length of regimen	49
2.3	Efficacy as a gametocytocidal drug for P. falciparum	
	malaria	49
3.	Tolerability and safety of primaquine	61
3.1	Tolerability and minor adverse effects	61
3.2	Glucose-6-phosphate dehydrogenase deficiency	
	and haemolysis	63
3.2.1	Pathogenesis of haemolysis in glucose-6-phosphate	
	dehydrogenase-deficient patients after primaquine	
	administration	64
3.2.2	Drugs that cause haemolysis in glucose-6-phosphate	
	dehydrogenase-deficient patients	73
3.2.3	Chlorproguanil-dapsone	74
3.2.4	Regional prevalence of glucose-6-phosphate	
	dehydrogenase deficiency	77

Annex 4.	Reports to the Uppsala Monitoring Centre	
Annex 3.	Studies of the safety of pamaquine	197
Annex 2.	Studies of the safety of primaquine	137
Annex 1.	New WHO recommendation on primaquine as <i>P. falciparum</i> gametocytocide	135
5.	References	113
4.	Conclusions	111
3.4.4	Limitations of the studies	108
	different primaquine regimens	105
3.4.3	Incidence of severe adverse events associated with	
3.4.2	of primaquine	102
240	and primaquine	101
3.4.1	Deaths reported after administration of pamaquine	
	in various populations	101
3.4	Incidence of severe adverse events due to primaquine	
	events associated with administration of primaguine	100
3.3.3	Reports to the Uppsala Monitoring Centre of adverse	55
3.3.2	administration of primaguine	00
3.3.⊥ 2.2.0	Van beamplutie powers advares events due to	95
2.2.4	other severe adverse events	94
3.3	Reports of primaquine-induced haemolysis and	
3.2.9	Methaemoglobinaemia	93
3.2.8	Blackwater fever	91
3.2.7	Haemolytic anaemia and malaria	87
	deficiency	83
3.2.6	Diagnosis of glucose-6-phosphate dehydrogenase	
3.2.5	Glucose-6-phosphate dehydrogenase variants	80

### **Abbreviations**

ACT	artemisinin-based combination therapy
CI	confidence interval
CYP	cytochrome P450
G6PD	glucose-6-phosphate dehydrogenase
Hb	haemoglobin
MAO	monoamine oxidase
NAD+	nicotinamide adenine dinucleotide
NADP+	nicotinamide adenine dinucleotide phosphate
NADPH	reduced form of NADP+
PCR	polymerase chain reaction
PQ	primaquine
RBC	red blood cell
SP	sulfadoxine-pyrimethamine
US(A)	United States (of America)
WHO	World Health Organization
WHO	World Health Organization

#### Acknowledgements

We are very grateful to those people who contributed material for this review, which is a comprehensive compilation of published and unpublished studies on the safety of 8-aminoquinolines. We are particularly grateful to Anatoly Kondrashin for providing studies on mass administration of primaquine to populations with a relatively high prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency, to Rosalind Howes for her maps of the prevalence of G6PD deficiency and to Naman Shah for allowing us to use his dissertation on *P. falciparum* gametocytaemia in India in 2012.

The review of historical documents at WHO by Elizabeth Ashley was facilitated by the kind, expert assistance of Andrea Bosman, Marie Villemin-Partow, Pascal Ringwald, Corinne Jegouzo, Aafje Rietveld and Tomas Allen. Additional documents were retrieved from the library of the Institut d'Histoire de la Médecine et de la Santé (University of Geneva) and the League of Nations Archive in Geneva with the help of Nathalie Fiore and Jacques Oberson, respectively. Many articles that could not be retrieved online at the authors' institutions were obtained by Jeanne Packer from Oxford University. The Uppsala Monitoring Centre kindly provided all their files on adverse drug reactions attributed to ingestion of primaquine.

This review was compiled primarily for a WHO evidence review group on the safety and effectiveness of single-dose primaquine as a *P. falciparum* gametocytocide. Contributions and recommendations made by members of the group attending a meeting in Bangkok, Thailand (13–15 August 2012), were added to the final draft.

Funding for the production of this report was gratefully received from the United Kingdom Department for International Development and the Bill & Melinda Gates Foundation.

#### 预览已结束,完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 27851